Adenovirus Vaccines in Military Recruit Populations: A Cost-Benefit Analysis

In 1966, the Army instituted an Adenovirus Surveillance Program to monitor acute respiratory disease (ARD) in recruit populations and the efficacy of adenovirus (ADV) vaccines in reducing ARD associated with ADV types 4 and 7. Between 1966 and 1971, the total cost of the surveillance program, includ...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1973-12, Vol.128 (6), p.745-752
Main Authors: Collis, Peter B., Dudding, Burton A., Winter, Phlllip E., Russell, Philip K., Buescher, Edward L.
Format: Article
Language:English
Subjects:
Adenoviridae Infections - prevention & control
Adenoviruses
Adult respiratory distress syndrome
Cost benefit ratio
Cost estimates
Costs and Cost Analysis
Diseases
Hospitalization
Immunization
Military Medicine
Military recruitment
Original Articles
Respiratory diseases
Respiratory Tract Infections - prevention & control
Statistics as Topic
United States
Vaccination
Viral Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 1966, the Army instituted an Adenovirus Surveillance Program to monitor acute respiratory disease (ARD) in recruit populations and the efficacy of adenovirus (ADV) vaccines in reducing ARD associated with ADV types 4 and 7. Between 1966 and 1971, the total cost of the surveillance program, including vaccine development, purchases, and administration, was estimated to be $4.83 million. In 1970 and 1971, when types 4 and 7 ADV vaccines were first used together for immunization of recruits entering basic training, it was estimated that these vaccines prevented 26,979 hospitalizations due to ARD. Direct and indirect costs associated with the hospitalization of one trainee with ARD amount to $279 (in 1971 dollar values). Thus the dollar estimate of benefits derived from use of these vaccines was 26,979 times $279, or $7.53 million. Based on these data, benefits derived from immunization ($7.53 million) outweigh the costs associated with immunization ($4.83 million), yielding a favorable benefit-cost ratio of 1.56.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/128.6.745